Lista de obras -

AIDS 2002. Virology: overview

artículo científico publicado el 1 de enero de 2002

Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).

artículo científico publicado en 2005

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

artículo científico publicado en 2002

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

artículo científico publicado en 2003

Cell-to-cell infection by HIV contributes over half of virus infection

artículo científico publicado en 2015

Clinically validated genotype analysis: guiding principles and statistical concerns.

artículo científico publicado en 2004

Contribution of Recombination to the Evolution of Human Immunodeficiency Viruses Expressing Resistance to Antiretroviral Treatment

artículo científico publicado en 2007

Corrigendum: Quantifying the Antiviral Effect of IFN on HIV-1 Replication in Cell Culture

artículo científico publicado en 2015

Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene

artículo científico publicado en 2012

Delaying Reverse Transcription Does Not Increase Sensitivity of HIV-1 to Human TRIM5α ⬇️

artículo científico publicado el 8 de enero de 2013

Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay

artículo científico publicado en 2010

Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine

artículo científico publicado en 2005

Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1.

artículo científico publicado en 2005

Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA).

artículo científico publicado en 2009

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure

artículo científico publicado en 2004

Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype

artículo científico publicado en 2002

Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients

artículo científico publicado en 2006

Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B.

artículo científico publicado en 2006

Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses

artículo científico publicado en 2008

Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity

artículo científico publicado en 2011

Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss

artículo científico publicado en 2009

Genetically intact but functionally impaired HIV-1 Env glycoproteins in the T-cell reservoir.

artículo científico publicado en 2017

HIV Drug Resistance

article

HIV resistance to raltegravir

artículo científico publicado en 2009

HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity.

scientific article published on 07 August 2009

High level of susceptibility to human TRIM5α conferred by HIV-2 capsid sequences.

artículo científico publicado en 2013

Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity

artículo científico publicado en 2005

Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.

artículo científico publicado en 2007

Hypermutation of HIV-1 DNA in the Absence of the Vif Protein ⬇️

artículo científico publicado el 16 de mayo de 2003

Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations

artículo científico publicado en 2003

Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.

artículo científico publicado en 2004

Impact of the HIV integrase genetic context on the phenotypic expression and in vivo dynamics of integrase inhibitor resistance mutations

artículo científico publicado en 2013

Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations

artículo científico publicado en 2014

In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations.

artículo científico publicado en 2009

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus

artículo científico publicado en 2004

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

artículo científico publicado en 2004

Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109)

artículo científico publicado en 2006

Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1

artículo científico publicado en 2007

Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy

scientific article published on 01 January 2006

Microtubule-associated proteins 1 (MAP1) promote human immunodeficiency virus type I (HIV-1) intracytoplasmic routing to the nucleus

artículo científico publicado en 2014

Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type

artículo científico publicado en 2009

Modulation of TRIM5α Activity in Human Cells by Alternatively Spliced TRIM5 Isoforms ⬇️

artículo científico publicado el 1 de junio de 2011

Multidrug-Resistant HIV-1 RNA and Proviral DNA Variants Harboring New Dipeptide Insertions in the Reverse Transcriptase pol Gene

artículo científico publicado el 1 de enero de 2002

Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection

artículo científico publicado en 2008

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial

artículo científico publicado en 2002

Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen

artículo científico publicado en 2008

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

artículo científico publicado en 2003

Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles

artículo científico publicado en 2013

Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues

artículo científico publicado en 2005

Role of Gag in HIV Resistance to Protease Inhibitors

artículo científico publicado en 2010

Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.

scientific article published on April 2004

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients

artículo científico publicado en 2006

Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.

artículo científico publicado en 2004

Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results

artículo científico publicado en 2007

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

artículo científico publicado en 2006

Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.

artículo científico publicado en 2009

Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial

artículo científico publicado en 2016

Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1.

artículo científico publicado en 2010

Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir

artículo científico publicado en 2007

Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures

artículo científico publicado en 2004

Lista de obras de

AIDS 2002. Virology: overview

Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

Cell-to-cell infection by HIV contributes over half of virus infection

Clinically validated genotype analysis: guiding principles and statistical concerns.

Contribution of Recombination to the Evolution of Human Immunodeficiency Viruses Expressing Resistance to Antiretroviral Treatment

Corrigendum: Quantifying the Antiviral Effect of IFN on HIV-1 Replication in Cell Culture

Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene

Delaying Reverse Transcription Does Not Increase Sensitivity of HIV-1 to Human TRIM5α ⬇️

Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay

Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine

Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1.

Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA).

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure

Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype

Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients

Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B.

Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses

Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity

Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss

Genetically intact but functionally impaired HIV-1 Env glycoproteins in the T-cell reservoir.

HIV Drug Resistance

HIV resistance to raltegravir

HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity.

High level of susceptibility to human TRIM5α conferred by HIV-2 capsid sequences.

Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity

Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.

Hypermutation of HIV-1 DNA in the Absence of the Vif Protein ⬇️

Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations

Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.

Impact of the HIV integrase genetic context on the phenotypic expression and in vivo dynamics of integrase inhibitor resistance mutations

Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations

In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations.

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109)

Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1

Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy

Microtubule-associated proteins 1 (MAP1) promote human immunodeficiency virus type I (HIV-1) intracytoplasmic routing to the nucleus

Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type

Modulation of TRIM5α Activity in Human Cells by Alternatively Spliced TRIM5 Isoforms ⬇️

Multidrug-Resistant HIV-1 RNA and Proviral DNA Variants Harboring New Dipeptide Insertions in the Reverse Transcriptase pol Gene

Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial

Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles

Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues

Role of Gag in HIV Resistance to Protease Inhibitors

Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients

Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.

Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.

Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial

Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1.

Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir

Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures